Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
The company has posted net profit of Rs. 283 crore for the 6 months period ended September 30, 2025
Dabur India has reported total income of Rs. 3,331.45 crore during the period ended September 30, 2025
Tatva Chintan Pharma Chem has reported total income of Rs. 124.52 crore during the period ended September 30, 2025
With over two decades of extensive experience, Lal has established himself as a transformational leader in the FMCG and consumer goods sectors
Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood
Subscribe To Our Newsletter & Stay Updated
